Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women

Journal of Bone and Mineral Research

Volumn 28, Issue 8, 2013, Pages 1793-1803

  Wolf, Myles ^a   Koch, Todd A ^b   Bregman, David B ^b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Luitpold Pharmaceuticals Inc   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

FGF23; IRON; phosphate; PTH; vitamin D

Indexed keywords

CALCITRIOL; FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; IRON DEXTRAN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; OSTEOCYTE; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; UTERUS BLEEDING;

EID: 84881241741     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1923     Document Type: Article

References (26)

1. Lyseng-Williamson KA, Keating GM., Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009; 69: 739-56.
2. Barish CF, Koch T, Butcher A, Morris D, Bregman DB., Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia. 2012; 2012: 172104.
3. Breymann C, Gliga F, Bejenariu C, Strizhova N., Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101: 67-73.
4. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C., FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141: 846-53.
5. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C., A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103: 1182-92.
6. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD., A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011; 26: 1599-607.
7. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R., Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008; 199: 435-7.
8. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A., Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007; 110: 267-78.
9. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49: 2719-28.
10. Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB., Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomised, active-controlled, multi-centre study. Nephrol Dial Transplant. Epub. 2012 Dec 5. DOI: 10.1093/ndt/gfs528
11. Okada M, Imamura K, Fuchigami T, Omae T, Iida M, Nanishi F, Murakami M, Ohgushi H, Yao T, Fujita K, Ogawa K., [Two cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide]. Nihon Naika Gakkai Zasshi. 1982; 71: 1566-72. Japanese
12. Okada M, Imamura K, Iida M, Fuchigami T, Omae T., Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr. 1983; 61: 99-102.
13. Sato K, Nohtomi K, Demura H, Takeuchi A, Kobayashi T, Kazama J, Ozawa H., Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone. 1997; 21: 57-64.
14. Sato K, Shiraki M., Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998; 45: 431-9.
15. Schouten BJ, Doogue MP, Soule SG, Hunt PJ., Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009; 46: 167-9.
16. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M., Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011; 33: 421-6.
17. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB., Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-9.
18. Mani LY, Nseir G, Venetz JP, Pascual M., Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010; 90: 804-5.
19. Juppner H, Wolf M, Salusky IB., FGF-23: more than a regulator of renal phosphate handling?. J Bone Miner Res. 2010; 25: 2091-7.
20. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG., FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94: 2332-7.
21. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE., Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108: E1146-55.
22. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ., Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011; 96: 3541-9.
23. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M., Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-92.
24. Bhattacharyya N, Chong WH, Gafni RI, Collins MT., Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012; 23: 610-8.
25. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T., Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98: 6500-5.
26. Szczech LA, Bregman DB, Morris D, Butcher A, Koch TA, Goodnough LT, Onken JE., Comparison of high dose ferric carboxymaltose to oral or IV iron in subjects with iron deficiency anemia not suitable for oral iron. J Am Soc Nephrol. 2012; 22: 435A.